课题基金 / 基金详情

Chemical genomics screening of drugs modulating functions of telomere/telomerase

Chemical genomics screening of drugs modulating functions of telomere/telomerase
端粒/端粒酶功能调节药物的化学基因组学筛选
批准号:
18390040
负责人:
MIZUKAMI Tamio
金额:
$8.75万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

MIZUKAMI Tamio的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In order to discover new telomerase inhibitors or new agents that act on telomere regulation mechanism which does not based on telomerase inhibition, we developed an unprecedented unique screening method with induction of shortened telomere as an activity indicator by a forward chemical approach using a yeast strain with shortened telomere length and found antimicrobial, anticancer compounds USC 1025A and chrolactomycin (TEY7) produced by microorganisms as active compounds. It was revealed that these compounds possess telomere-shortening-inducing activity as well as telomerase inhibitory activity within tumor cells but neither detailed mechanism of action nor direct target molecules are still unknown.The objectives of the study is to elucidate the mechanism of action of these compounds on the molecular level by identifying intracellular target molecules to which the compounds bind directly and to validate the possibility of the identified molecules as new molecular targets of anticancer agents by analyzing the function of the identified target molecules in telomere regulation and cancerous change of cells.In the study, we used biotin-labeled probes of UCS1025A and TEY7 and found the protein that binds to respective compound. As these labeled proteins are thought to contain a direct active site of the compounds, we made an analysis by in-gel protease digestion and mass spectrometry to identify binding protein.It can be expected that identification of the target molecules of these compounds and elucidation of their mechanisms of action will provide a new drug discovery approach that leads to development of new anticancer agents acting specifically on cancer cells with much less side effects compared to existing anticancer drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Telomerase Inhibitors Identified by a Forward Chemical Genetics Approach Using a Yeast Strain with Shortened Telomere Length.
使用端粒长度缩短的酵母菌株通过正向化学遗传学方法鉴定出新型端粒酶抑制剂。
DOI: --
发表时间: 2006
期刊: Chem Biol. 13
影响因子: --
作者: [Nakai, R., Ishida, H., Asai, A., ogawa, H., Yamamoto, Y., Kawasaki, K., Akinaga, S., Mizukami, T., Yamashita, Y.]
通讯作者: Y.
酵母宿主のフォワードケミカルゲノミクスによる抗癌剤創薬の展開
利用酵母宿主的正向化学基因组学开发抗癌药物
DOI: --
发表时间: 2007
期刊: 化学と生物 45
影响因子: --
作者: [山下 順範, 水上 民夫]
通讯作者: 水上 民夫
Anti-cancer drug discovery by a yeast-based forward chemical genomics approach.
通过基于酵母的正向化学基因组学方法发现抗癌药物。
DOI: --
发表时间: 2007
期刊: Kagaku to Seibutsu. 45
影响因子: --
作者: [Yamashita Y, Mizukami T]
通讯作者: Mizukami T
Oncogenic properties of human dynactin-associated protein (dynAP)
国内基金
海外基金
子宫内膜间质与巨噬细胞之间通过Protein S-MerTK-Apelin信号对 话促进子宫腺肌病蜕膜化缺陷的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    吕海宁
  • 依托单位:
有翅与无翅蚜虫差异分泌唾液蛋白Cuticular protein在调控植物细胞壁免疫中的功能
  • 批准号:
    32372636
  • 项目类别:
    面上项目
  • 资助金额:
    50.00万元
  • 批准年份:
    2023
  • 负责人:
    郭慧娟
  • 依托单位:
胆固醇合成蛋白CYP51介导线粒体通透性转换诱发Th17/Treg细胞稳态失衡在舍格伦综合征中的作用机制研究
  • 批准号:
    82370976
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    郑凌艳
  • 依托单位:
原发性开角型青光眼中SIPA1L1促进小梁网细胞外基质蛋白累积升高眼压的作用机制
  • 批准号:
    82371054
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    郭涛
  • 依托单位: